RELMADA THERAPEUTICS, INC. cotiza a 3.36 USD y tiene una capitalización bursátil de $358M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive b…
| Periodo | 2026-11 | 2026-08 | 2026-03 | 2025-11 |
|---|---|---|---|---|
| Real | — | $-0.11 | $-0.29 | $-0.30 |
| Estimado | $-0.14 | $-0.20 | $-0.14 | $-0.04 |
| Sorpresa | — | +45.0% | -107.1% | -650.0% |
| Métrica | RLMD | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -66.3% | -40.4% | -25.9% |
| ROA | -61.0% | -32.0% | -29.0% |
| Current Ratio | 14.62 | 2.84 | +11.78 |
| Debt / Equity | — | 0.28 | — |